Celltech's results include goodwill and exceptional charges of £451.8m as it swallows Medeva. The ...
Celltech's results include goodwill and exceptional charges of £451.8m as it swallows Medeva. The company expects £25m in cost savings to flow through to the bottom line this year, a higher than expected figure. The company has enjoyed the support of the market after a deal to develop its rheumatoid arthritis and Crohn's disease treatment CDP 870 on very favourable terms. Celltech has 12 products in various stages of development and remains the blue riband pick of the European biotechs.
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
